Depiction of Prostate Cancer Treatment Alternatives in Greece

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: August 8, 2008
Last updated: October 13, 2009
Last verified: October 2009

A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.

  • Target Group: Patients with locally advanced or metastatic prostate cancer.
  • The first 10 consecutive patients records that meet the entry criteria.

Locally Advanced or Metastatic Prostate Cancer.

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Depiction of Prostate Cancer Treatment Alternatives in Greece

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percentage of patients treated by each treatment alternative. [ Time Frame: Between 2002 - 2008 ]

Secondary Outcome Measures:
  • To depict sociodemographic characteristics and comorbidities. [ Time Frame: Between 2002 - 2008 ]

Estimated Enrollment: 310
Study Start Date: January 2008
Study Completion Date: March 2009

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer


Inclusion Criteria:

  • Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
  • Patients that received Hormonal therapy.

Exclusion Criteria:

  • Males that are aged less than 18 years
  Contacts and Locations
Please refer to this study by its identifier: NCT00733213

Research Site
Athens, Greece
Research Site
Karditsa, Greece
Research Site
Serres, Greece
Research Site
Xsanthi, Greece
Sponsors and Collaborators
Study Director: Panagiotis Pontikis, MD AstraZeneca Greece
  More Information

No publications provided

Responsible Party: Dr Pontikis Panagiotis, MD Medical and Regulatory Affairs Director, AstraZeneca, SA Greece Identifier: NCT00733213     History of Changes
Other Study ID Numbers: NIS-OGR-DUM-2007/1
Study First Received: August 8, 2008
Last Updated: October 13, 2009
Health Authority: Greece: National Organization of Medicines

Keywords provided by AstraZeneca:
Prostate Cancer, Treatment alternatives, Metastasis

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on April 16, 2014